bioactiv
materi
antibacteri
properti
signific
medic
interest
antibacteri
bioactiv
materi
prepar
simpl
combin
antibacteri
substanc
materi
hydrogel
ceram
metal
polym
differ
form
fibr
foam
film
gel
deliveri
antibacteri
molecul
lead
kill
bacteria
anoth
approach
design
materi
possess
antibacteri
properti
especi
surfac
materi
applic
found
orthopaed
cardiovascular
graft
mean
reduc
incid
infect
wound
care
industri
use
antibacteri
bioactiv
materi
control
infect
alway
first
line
wound
treatment
howev
still
consider
limit
includ
difficulti
treatment
infect
depth
control
biofilm
format
develop
gener
specif
antibacteri
bioactiv
materi
futur
bioactiv
materi
base
biomimet
materi
antibacteri
properti
develop
natur
resourc
minim
neg
impact
human
bodi
gramposit
organ
includ
staphylococcu
aureu
staphylococcu
epidermidi
enterococcu
faecium
enterococcu
faecali
streptococcu
pneumonia
report
sever
central
agenc
follow
bacteri
resist
trend
indic
preval
methicillinresist
aureu
mrsa
increas
vancomycinresist
e
faecium
vre
last
year
alon
resist
organ
repres
major
caus
morbid
mortal
hospit
patient
hospitalacquir
infect
hai
howev
problem
resist
gramposit
organ
limit
hospit
patient
outpati
also
affect
emerg
penicillinresist
pneumonia
prsp
caus
communityacquir
pneumonia
hospitalacquir
infect
healthcar
environ
attract
consider
worldwid
attent
past
year
owe
mani
occurr
outbreak
mrsa
vre
caus
morbid
mortal
search
methodolog
prevent
treat
infect
current
import
clinic
topic
estim
current
global
antiinfect
market
valu
us
billion
bioactiv
antibacteri
agent
account
sale
antibacteri
market
set
grow
us
billion
driven
uptak
newer
antibacteri
agent
glycopeptid
carbapenem
demonstr
resist
mrsa
vre
well
emerg
strain
pharmaceut
compani
continu
develop
new
gener
antibacteri
agent
cephalosporin
macrolid
quinolon
overcom
major
issu
drug
resist
addit
number
new
drug
class
effect
multidrugresist
organ
dihydrofol
reductas
inhibitor
dhfr
evalu
chapter
focu
bioactiv
materi
antibacteri
function
use
medic
devic
relat
health
care
industri
exampl
wound
care
dental
orthopaed
cardiovascular
antibacteri
materi
discuss
chapter
includ
antibacteri
inorgan
polym
bioglass
ceram
glassceram
zeolit
antibacteri
composit
bone
cement
antibacteri
metal
antibacteri
polym
plastic
fig
antibacteri
materi
antibacteri
ceram
recent
receiv
great
attent
wide
rang
applic
includ
electron
medic
applic
variou
form
fibr
fabric
build
materi
bioactiv
materi
medicin
antibacteri
medicin
commonli
use
treatment
infect
definit
antibacteri
bioactiv
materi
materi
possess
activ
destroy
bacteria
suppress
growth
abil
reproduc
past
sever
year
infecti
diseas
manag
becom
increas
challeng
physician
manag
bacteri
infect
becom
difficult
due
emerg
drugresist
bacteria
alarm
increas
number
resist
gramposit
organ
last
year
storag
contain
devic
without
incorpor
certain
metal
ion
ceram
bioceram
includ
bioglass
ceram
glassceram
exhibit
excel
antibacteri
properti
among
metal
element
heavi
metal
silver
zinc
copper
mercuri
tin
lead
bismuth
cadmium
chromium
thallium
possess
antibacteri
properti
exchang
metal
impart
antibacteri
activ
inorgan
polym
zeolit
zirconium
antibacteri
effect
silversupport
zirconium
phosphat
silica
gel
due
releas
silver
ion
activ
oxygen
base
catalyt
action
silver
see
fig
common
practic
incorpor
antibacteri
materi
curabl
resin
obtain
antibacteri
composit
medic
applic
exampl
load
polymethylmethacryl
pmma
bone
cement
antibiot
reduc
infect
rate
propos
antimicrobi
chlorhexidin
incorpor
classif
antibacteri
bioactiv
materi
glass
ionom
cement
gic
resinmodifi
glass
ionom
cement
rmgic
improv
antibacteri
properti
agent
describ
gold
standard
antibacteri
applic
approach
direct
incorpor
antibacteri
medicin
bone
cement
system
monom
bromid
mdpb
see
fig
potenti
polymer
incorpor
dental
resinbas
materi
dentin
bond
primerresin
make
composit
bactericid
activ
advers
effect
biocompat
composit
base
biodegrad
polym
ceram
bioglass
found
wide
applic
bone
tissu
repair
inclus
antibacteri
properti
combat
bone
tissu
infect
attract
approach
clinic
applic
design
bioactiv
materi
achiev
simpl
blend
mix
antibacteri
materi
antibacteri
molecul
bulk
achiev
control
releas
antibacteri
substanc
howev
surfac
normal
place
schemat
diagram
antibacteri
effect
composit
contain
nonreleas
silversupport
powder
activ
oxygen
produc
base
catalyt
action
silver
composit
show
antibacteri
effect
contact
bodi
surfac
antiinfect
function
sometim
critic
tokuda
et
al
develop
method
blend
pla
calcium
carbon
siloxan
mercapto
group
form
composit
guid
bone
regener
mercapto
group
capabl
adsorb
silver
composit
surfac
ensur
antibacteri
properti
bone
implant
silver
ion
long
recogn
possess
strong
inhibitori
bactericid
effect
well
broad
spectrum
antimicrobi
activ
silverdop
titanium
dioxid
powder
show
mark
antibacteri
activ
even
without
presenc
light
antibacteri
activ
silverdop
titania
materi
influenc
method
prepar
solgel
ionexchang
melt
effect
reactant
sulfat
chlorid
organ
deriv
calcin
temperatur
anoth
method
produc
antibacteri
metal
deposit
nobl
metal
surfac
anoth
materi
form
thin
film
use
process
call
reactiv
magnetron
sputter
form
physic
vapour
deposit
exampl
nucryst
develop
technolog
produc
nanosilv
antibacteri
thin
metal
surfac
process
review
follow
vacuum
chamber
pure
silver
bombard
posit
ion
liber
sputter
individu
atom
silver
atom
activ
entiti
known
plasma
often
refer
fourth
state
matter
silver
atom
recondens
form
new
highenergi
nanocrystallin
structur
substrat
highdens
polyethylen
nonadher
wound
care
dress
nanocryst
silver
use
nucryst
pharmaceut
exist
medic
devic
emerg
pharmaceut
product
line
nm
develop
target
wide
rang
potenti
pharmaceut
product
titanium
dioxid
tio
ultraviolet
uva
wellrecogn
bactericid
effect
treatment
bioimplantrel
infect
mani
commerci
product
develop
base
technolog
antibacteri
applic
hospit
bacteriapron
environ
metal
copper
cu
silver
ag
deposit
photocatalyt
tio
coat
purpos
enhanc
antibacteri
activ
make
coat
work
even
dark
exampl
antibacteri
tile
base
technolog
work
effect
dark
illumin
condit
effect
much
higher
light
extend
fabric
photocatalyt
modifi
agtio
coat
silicon
cathet
medic
tube
effect
steril
microorgan
dark
condit
coat
use
indwel
cathet
use
insid
bodi
guid
light
problem
design
antibacteri
polym
three
approach
antibacteri
molecul
incorpor
system
coval
bond
physic
mix
physic
complex
fig
approach
perman
attach
antibacteri
moieti
polym
system
via
coval
bond
exampl
antibacteri
moieti
differ
benzophenon
chromophor
group
incorpor
onto
cotton
fabric
react
acid
via
paddrycur
method
antibacteri
assess
benzophenon
derivativetr
cotton
fabric
perform
aureu
e
coli
cotton
fabric
demonstr
effect
antibacteri
abil
shown
fig
cellulos
fabric
chemic
modifi
triazin
deriv
contain
multication
benzyl
group
shown
fig
novel
cellulos
biomateri
contain
multication
benzyl
group
display
excel
durabl
antibacteri
properti
polym
biocid
activ
design
introduc
dival
transit
metal
salt
metal
ion
zn
cu
polym
main
chain
form
complet
network
polym
found
applic
antibacteri
coat
solubl
dimethyl
sulfoxid
dmso
dimethyl
acetamid
dmac
dimethyl
formamid
dmf
particular
poli
urethaneurea
puu
poli
urethaneeth
pue
satisfactori
biocompat
biodegrad
properti
could
potenti
lead
varieti
bloodcontact
applic
metalcontain
polym
util
sustain
resourc
linse
oilbas
polyesteramid
also
develop
antibacteri
purpos
found
minor
incorpor
coval
bond
antibacteri
moieti
cotton
fabric
zinc
linse
oilbas
polyesteramid
exhibit
improv
antibacteri
activ
e
coli
aureu
plastic
combin
low
cost
good
mechan
properti
easi
process
wide
use
prepar
biomed
devic
food
packag
sometim
antibacteri
properti
essenti
obtain
plastic
antibacteri
properti
three
gener
approach
shown
fig
waterinsolubl
antibacteri
plastic
via
chemic
bond
approach
type
environment
friendli
disinfect
materi
leach
chemic
environ
attract
much
attent
exampl
quaternari
ammonium
salt
qa
moieti
polymer
plastic
organicinorgan
hybrid
coat
contain
qa
bond
organicinorgan
network
prepar
tetraethoxysilan
triethoxysilan
termin
poli
ethylen
glycol
blockpoli
ethylen
use
solgel
process
nalkyl
poli
moieti
also
synthes
demonstr
effect
longterm
antibacteri
properti
chemic
bond
approach
trial
achiev
antibacteri
composit
simpl
blend
carri
two
approach
alter
resin
compon
addit
solubl
antimicrobi
agent
resin
matrix
b
immobil
antibacteri
compon
resin
matrix
util
antibacteri
monom
approach
prepar
antibacteri
plastic
alter
filler
compon
addit
compon
silver
filler
silvercontain
silica
glass
silver
zeolitesilv
apatit
silversupport
zirconium
phosphatesilversupport
silica
gel
b
addit
nonbiocid
compon
filler
antimicrobi
polym
photocatalyt
ingredi
expos
light
gener
free
radic
polyvinyl
chlorid
pvc
wide
accept
biomateri
medic
applic
microbi
attack
prevent
incorpor
effect
biocid
also
known
biostabil
plastic
wide
rang
biocid
avail
includ
among
other
obpa
trichlorohydroxydiphenyleth
triclosan
noctylisothiazolinon
oit
dcoit
mercaptopyridinenoxid
pyrithion
butylbenzisothiazolinon
butylbit
metalbas
biocid
organotin
silver
nonbiocid
addit
includ
inher
antimicrobi
polym
photocatalyt
ingredi
expos
light
gener
free
radic
develop
antibacteri
pvc
product
variou
type
antibacteri
filler
incorpor
blend
system
make
composit
process
finish
product
exampl
zeolit
contain
ag
cu
zinc
zn
powder
incorpor
pvc
blend
manufactur
plastic
product
polym
thermoplast
olefin
tpo
thermoplast
elastom
tpe
polyurethan
contain
plastic
potenti
provid
carbon
sourc
microbi
growth
may
still
requir
protect
antimicrobi
organ
antimicrobi
addit
compound
polym
diffus
surfac
destroy
microorgan
interf
enzym
activ
antimicrobi
addit
surfac
use
wash
away
addit
polym
matrix
continu
come
surfac
provid
extend
perform
strongest
growth
inorgan
silverbas
biocid
recent
util
broad
rang
polym
applic
function
antibacteri
polym
also
use
coat
materi
local
deliveri
antibiot
implant
gener
must
biocompat
biodegrad
releas
profil
activ
substanc
need
meet
clinic
requir
commonli
use
coat
materi
polyest
urethan
polyesterpolyurethan
contain
differ
ratio
poli
lactic
acid
diol
poli
caprolacton
diol
bioresorb
polym
pla
coat
materi
research
altern
antibacteri
materi
synthet
one
attract
topic
mani
year
natur
antimicrobi
peptid
amp
popular
natur
biopolym
term
attent
receiv
cation
anion
peptid
typic
exampl
cecropin
defensin
thionin
aminoacidenrich
class
histonederiv
compound
betahairpin
lactoferrin
neuropeptidederiv
molecul
asparticacidrich
molecul
aromat
dipeptid
oxygenbind
protein
bacteriocin
bacteriocin
usual
nontox
odourless
colourless
tasteless
sinc
mode
action
differ
convent
antibiot
includ
target
much
narrow
rang
bacteri
speci
crossresist
bacteriocin
systemicallyadminist
antibiot
would
unlik
develop
also
gener
inactiv
one
proteolyt
enzym
present
digest
tract
human
would
metabol
like
dietari
protein
final
bacteriocin
natur
product
may
better
public
accept
synthet
chemic
agent
lactoferrin
formerli
known
lactotransferrin
glycoprotein
member
transferrin
famili
belong
protein
capabl
bind
transfer
fe
ion
first
isol
sorensen
sorensen
bovin
milk
lactoferrin
affect
growth
prolifer
varieti
infecti
agent
includ
gramposit
neg
bacteria
virus
protozoa
fungi
rapid
growth
nanotechnolog
spur
signific
interest
medic
applic
nanomateri
mani
materi
nanoscal
exhibit
superior
antibacteri
properti
origin
nanoscal
commonli
report
antibacteri
nanomateri
includ
silver
nanoparticl
nag
nanosilverbas
nanocomposit
silverliposom
chitosanbas
nanobiopolym
photocatalyt
tio
fullerol
aqueou
fulleren
nanoparticl
carbon
nanotub
cnt
among
nanomateri
nanosilv
receiv
attent
nair
et
al
report
onepot
synthesi
silver
nanoparticlepolym
composit
agpnc
water
involv
polycondens
methoxybenzyl
chlorid
meobzcl
directli
silver
nanoparticl
surfac
room
temperatur
lead
highli
solubl
antimicrobi
nanocomposit
composit
solubl
rang
organ
solvent
precipit
reaction
vessel
make
separ
simpl
solut
composit
cast
directli
substrat
made
freestand
film
materi
found
stabl
nearli
year
rang
substrat
shown
becom
antibacteri
direct
coat
applic
materi
claim
simpl
onepot
approach
type
produc
organicsolubl
antibacteri
coat
could
wide
implic
barani
et
al
report
method
incorpor
nanosilv
particl
liposom
structur
larg
silverliposom
nanocomposit
transform
smaller
silverliposom
nanocomposit
nm
sonic
treatment
stabil
silver
nanoparticl
variou
concentr
show
good
antibacteri
activ
staphylococcu
aureu
gramposit
bacterium
escherichia
coli
gramneg
bacterium
apart
liposom
silver
ag
silver
sulfid
ag
nanoparticl
also
synthes
sago
biopolym
starch
matrix
hydrogelbas
nanosilv
nanomateri
polysaccharidebas
nanosilv
system
chitosan
algin
high
concentr
releas
silver
nanoparticl
composit
water
environ
particular
hydrogel
system
antimicrobi
result
show
nanocomposit
system
display
effect
bactericid
activ
toward
gramposit
gramneg
bacteria
howev
hydrogel
show
cytotox
effect
toward
three
differ
eukaryot
cell
line
nanoparticl
immobil
gel
matrix
exert
antimicrobi
activ
simpl
contact
bacteri
membran
taken
intern
eukaryot
cell
novel
find
could
contribut
advantag
respond
grow
concern
toxic
nanoparticl
facilit
use
silverbiopolym
composit
prepar
biomateri
despit
stringent
steril
asept
procedur
bacteri
infect
remain
major
impedi
util
medic
implant
includ
cathet
artifici
prosthet
subcutan
sensor
indwel
devic
respons
half
nosocomi
infect
estim
one
million
case
per
year
usa
alon
deviceassoci
infect
result
bacteri
adhes
subsequ
biofilm
format
implant
site
much
research
focus
develop
medic
devic
surfac
resist
bacteri
adhes
gener
mode
antimicrobi
action
surfac
may
extern
b
surfac
activ
c
time
releas
see
fig
mode
action
advantag
disadvantag
extern
mode
repres
disinfect
appli
surfac
compromis
structur
integr
microorgan
contact
blanket
antimicrobi
approach
suffici
quantiti
kill
microorgan
may
also
affect
human
surfaceact
mode
repres
select
transferr
antimicrobi
surfac
agent
microorgan
toxic
accumul
occur
membran
disrupt
occur
caus
cellular
leakag
final
timereleas
mode
consist
discharg
antimicrobi
respons
environment
trigger
chang
surfac
ph
moistur
pressur
induct
either
latter
condit
may
initi
surfac
attach
antimicrobi
temperatur
chang
clinic
applic
antibacteri
materi
base
surfaceact
timereleas
mode
howev
gener
practic
first
mode
disinfect
wide
appli
routin
clean
regim
typic
applic
antibacteri
materi
rang
product
gener
hospit
equip
eg
hospit
bed
chair
healthcar
furnish
medic
packag
door
handl
highgrad
medic
devic
like
intraven
iv
access
system
urolog
devic
cathet
bone
cement
dental
repair
materi
vascular
graft
wound
care
product
product
antibacteri
properti
control
growth
bacteria
surfac
medic
devic
attempt
address
increas
problem
healthcareacquir
infect
three
gener
mode
antimicrobi
surfacemedi
activ
extern
b
surfac
activ
c
time
releas
wound
care
major
healthcar
market
estim
valu
us
billion
predict
grow
us
billion
industri
sector
antibacteri
materi
play
import
role
combat
wound
infect
one
develop
wound
care
market
found
favour
clinician
impregn
product
antimicrobi
reduc
risk
microbi
infect
earli
use
silver
wound
care
silver
sulphadiazin
agsd
cream
develop
treatment
burn
recent
trend
toward
use
wound
cover
dress
contain
silver
evid
today
select
foam
film
hydrocolloid
gauz
dress
silver
technolog
wound
dress
impregn
silver
commerci
avail
shown
tabl
thoma
mccubbin
compar
invitro
effect
variou
silvercontain
product
use
three
method
zone
inhibit
challeng
test
microbi
transmiss
test
demonstr
differ
variou
dress
result
staphylococcu
aureu
escherichia
coli
candida
albican
suggest
polyethylen
mesh
rapid
antimicrobi
effect
due
rapid
releas
silver
hydrocolloid
similar
slower
onset
activ
carbon
littl
activ
surfac
organ
absorb
dress
inactiv
silver
iodin
polyhexamethylen
biguanid
phmb
two
popular
antibacteri
agent
use
wound
dress
exampl
compani
smith
nephew
develop
cadexom
iodin
iodoflexa
iodosorba
threedimension
starch
lattic
form
spheric
microspher
trap
iodin
lattic
fluid
absorb
pore
size
lattic
increas
releas
iodin
polyhexamethylen
biguanid
phmb
also
known
polyhexanid
polyaminopropyl
biguanid
commonli
use
fastact
broad
spectrum
antimicrobi
provid
activ
wide
rang
bacteria
includ
mrsa
salmonella
spp
campylobact
spp
e
coli
virus
exampl
vantociltg
antimicrobi
independ
shown
provid
activ
fcov
felin
coronaviru
product
incorpor
phmbbase
wound
dress
product
includ
kerlix
excilon
telfa
tyco
healthcar
group
mansfield
massachusett
xcella
cellulos
wound
dress
antimicrobi
xylo
corp
langhorn
pennsylvania
cosmocil
cq
antimicrobi
arch
oxyzym
iodozym
activ
wound
heal
dress
base
biochemistri
enzym
reaction
system
gener
low
level
hydrogen
peroxid
iodin
claim
oxyzym
dress
produc
peak
surfac
concentr
iodin
approxim
time
lower
tradit
iodin
dump
dress
base
povidoneiodin
howev
concentr
iodin
suffici
produc
environ
hostil
bacteria
surfac
dress
antibacteri
materi
wide
use
dental
orthopaed
implant
mani
year
sinc
bacteria
still
concern
recurr
caus
failur
implant
usa
alon
annual
cost
symptomat
treatment
dental
infect
estim
billion
increas
billion
billion
also
report
infect
rate
total
joint
arthroplasti
rang
among
half
million
implant
use
usa
alon
complic
infect
implant
quit
often
lead
surgic
intervent
high
health
social
cost
exampl
estim
treatment
singl
episod
infect
arthroplasti
cost
bone
cement
antibiot
wide
accept
clinic
use
shown
tabl
bone
cement
antibiot
coat
contain
antibiot
orthopaed
devic
also
use
clinic
exampl
gentamicin
rel
broad
antibacteri
spectrum
load
polym
coat
titanium
implant
addit
antibiot
broad
antibacteri
spectra
instanc
cephalothin
carbenicillin
amoxicillin
cefamandol
tobramycin
vancomycin
use
coat
bone
implant
vascular
graft
infect
repres
one
challeng
issu
surgeri
incid
femor
site
infect
common
incid
infect
vascular
prosthet
implant
arteri
occlus
diseas
occur
approxim
patient
includ
earli
late
clinic
present
routin
excis
infect
peripher
arteri
graft
vascular
reconstruct
extraanatom
conduit
associ
mortal
rate
rang
amput
rate
clinic
data
report
situ
replac
rifampicinbond
prosthesi
accomplish
success
small
number
patient
show
promis
earli
result
advanc
manag
infect
vascular
prosthes
last
decad
led
improv
mortal
decreas
amput
rate
convent
excis
extraanatom
bypass
newer
method
includ
situ
graft
replac
antibioticimpregn
prosthet
appear
suitabl
lowvirul
epidermidi
infect
stone
et
al
implant
pmma
bead
load
antibiot
vancomycin
daptomycin
tobramycingentamicin
combin
treat
vascular
surgic
site
vss
infect
result
indic
antibioticload
pmma
bead
may
use
adjunct
contemporari
surgic
manag
vss
infect
involv
prosthet
graft
anoth
approach
treat
methicillinresist
staphylococcu
aureu
mrsa
epidermidi
prosthet
vascular
graft
infect
carri
situ
replac
rifampicin
bond
gelsoft
graft
intergard
silver
ig
collagen
silveracetateco
polyest
graft
use
replac
infect
vascular
prosthesi
situ
preliminari
result
small
seri
demonstr
favour
outcom
ig
graft
use
treat
infect
abdomin
aortic
graft
aneurysm
caus
organ
low
virul
larger
seri
longer
followup
requir
compar
role
ig
graft
treatment
option
infect
field
multicentr
clinic
studi
demonstr
intergard
silver
graft
safe
side
effect
primari
patenc
rate
excel
graft
infect
rate
low
despit
high
incid
nosocomi
infect
comparison
show
efficaci
collagen
silverco
polyest
gelatins
graft
rifampinsoak
vascular
graft
resist
infect
mrsa
escherichia
coli
carri
result
indic
collagen
silverco
graft
gelatins
graft
soak
rifampin
provid
resist
mrsa
e
coli
trend
toward
better
resist
without
statist
signific
e
coli
rifampin
silver
graft
compar
rifampinsoak
gelsoft
graft
without
sign
inflamm
intergard
silver
graft
antibiot
retent
polytetrafluoroethylen
ptfe
graft
prepar
use
three
antibioticbond
method
compar
follow
implant
arteri
circul
ciprofloxacin
silverciprofloxacin
bond
ptfe
surfac
surfactantmedi
direct
bond
method
bond
silverciprofloxacin
ptfe
graft
provid
effect
sourc
local
antibiot
releas
level
may
use
bypass
graft
contamin
wound
situ
replac
graft
infect
central
nervou
system
cn
infect
major
complic
vascular
stent
stent
impregn
gelatin
dip
rifampicin
shown
resist
methicillinresist
staphylococcu
aureu
anim
experi
man
tyrx
aigisrx
commerci
avail
antibacteri
envelop
use
cardiac
rhythm
manag
devic
crmd
pivitab
new
surgic
hernia
mesh
licens
c
r
bard
elut
power
antibiot
combin
minocyclin
rifampin
antibacteri
materi
wide
use
clinic
medic
devic
activ
substanc
antibacteri
molecul
present
matrix
surfac
devic
topic
dress
manag
wound
includ
surgic
acut
chronic
wound
burn
implant
includ
longterm
implant
artifici
joint
fixat
devic
sutur
pin
screw
cathet
stent
drain
signific
progress
made
term
develop
suitabl
biomateri
carrier
control
releas
profil
activ
substanc
antibacteri
surfac
interact
system
biolog
medium
clinic
efficaci
cours
control
manufactur
process
final
integr
devicemedicin
hybrid
togeth
regulatori
issu
market
biocidesdevic
still
mani
limit
develop
applic
antibacteri
materi
one
limit
select
antibacteri
substanc
potenti
lead
bacteri
resist
exampl
use
silver
increas
rapidli
field
wound
care
wide
varieti
silvercontain
dress
commonplac
report
section
wound
care
howev
concern
associ
overus
silver
consequ
emerg
bacteri
resist
rais
review
perciv
et
al
state
although
resist
heavi
metal
ag
studi
report
exact
mechan
known
littl
current
evid
emerg
microbi
resist
silver
unlik
case
antibiot
resist
antisept
ag
rare
sporad
certainli
widespread
use
ag
wound
care
potenti
pathogen
go
expos
agent
knowledg
silverresist
gene
exist
sporad
certain
type
bacteria
would
appropri
futur
studi
determin
actual
preval
gene
within
clinic
environment
set
current
knowledg
limit
therefor
advis
best
approach
keep
hygien
emphas
wound
care
use
wound
dress
antibacteri
materi
target
toward
applic
demonstr
benefit
anoth
limit
lack
ideal
control
releas
system
minim
cytotox
antibacteri
materi
could
potenti
lead
failur
woundheal
process
tissueimpl
integr
maxim
efficaci
antiinfect
properti
exampl
recent
publish
paper
review
clinic
evid
use
acticoat
tm
dress
burn
evid
suggest
acticoat
tm
improv
bacteri
clearanc
compar
silvercontain
dress
easi
use
sustain
releas
silver
allow
less
frequent
dress
chang
combin
low
toxic
level
make
possibl
ideal
dress
burn
wound
howev
despit
wide
use
acticoat
tm
burn
avail
evid
regard
use
burn
weak
one
studi
consid
level
evid
loe
welldesign
properli
report
random
control
trial
essenti
inform
clinic
decis
make
accord
wittayaareekul
prahsarn
ideal
wound
dress
follow
properti
provid
moistur
wound
heal
environ
ii
provid
thermal
insul
iii
remov
without
caus
trauma
wound
iv
remov
drainag
debri
v
free
particul
toxic
product
vi
promot
tissu
reconstruct
process
howev
still
difficult
get
ideal
element
one
singl
wound
dress
mention
antibacteri
function
therefor
factor
materi
also
limit
develop
advanc
antibacteri
materi
anoth
limit
difficulti
obtain
ideal
antibacteri
substanc
possess
follow
featur
effect
microorgan
costeffect
end
product
compat
ingredi
final
product
discolour
final
product
withstand
high
process
temperatur
effect
wide
ph
rang
low
toxic
human
extens
support
document
high
biodegrad
bring
new
antibacteri
substanc
market
featur
cost
high
manufactur
activ
ingredi
estim
cost
global
registr
million
take
year
conduct
toxicolog
test
anoth
year
region
govern
throughout
world
grant
registr
end
user
often
want
evalu
biocid
year
test
period
result
requir
small
potenti
market
size
biocid
manufactur
extend
product
line
turn
exist
activ
ingredi
new
applic
instead
develop
new
molecul
would
certainli
limit
develop
new
antibacteri
materi
clinic
applic
impend
environment
regul
europ
elsewher
present
major
challeng
supplier
biocid
european
union
eu
biocid
product
direct
bpd
flagship
reach
chemic
polici
forc
ration
mani
product
line
remov
larg
number
activ
ingredi
market
requir
manufactur
sourc
replac
green
activ
june
eu
regul
ec
registr
evalu
author
restrict
chemic
socal
reach
regul
enter
forc
reach
regul
impos
sweep
requir
manufactur
import
chemic
product
contain
particular
reach
impos
new
requir
produc
medic
devic
addit
euspecif
medic
devic
legisl
certainli
add
extra
burden
respect
develop
antibacteri
materi
use
antibacteri
bioactiv
substanc
medic
devic
applic
anoth
limit
consider
longev
effect
antibacteri
properti
use
antibacteri
materi
mean
necessari
follow
gener
hygien
requir
clean
exampl
pvc
floor
wall
cover
antibacteri
addit
promot
hygien
surfac
hospit
use
howev
stress
necessarili
follow
result
antibacteri
protect
surfac
longer
vulner
infect
convent
clean
method
compromis
contamin
usual
associ
soil
surfac
dirt
food
bodili
fluid
ideal
indwel
medic
devic
surfac
surfac
properti
healthi
live
bodi
would
resist
bacteria
adher
kill
bacteri
promot
growth
live
tissu
indwel
medic
devic
difficult
manufactur
hostmaintain
immun
defenc
system
usual
reject
foreign
bodi
intrus
bacteri
speci
constantli
chang
limit
devic
manufactur
process
expect
strong
growth
antimicrobi
materi
industri
includ
plastic
implant
medic
devic
follow
reason
market
demand
implant
medic
devic
antiinfect
effect
infect
microbi
contamin
common
factor
lead
failur
implant
clinic
market
advantag
valuead
antibacteri
product
gener
met
consum
favour
need
ensur
hygien
condit
industri
commerci
medic
institut
set
support
gain
regulatori
pressur
tradit
antimicrobi
oxybisphenoxarsin
obpa
pipe
pcp
tributyltinoxid
tbto
promot
search
new
natur
green
antibacteri
substanc
increas
concern
relat
diseas
transmiss
drive
demand
surfac
treat
antimicrobi
highend
industri
growth
particular
geograph
region
asia
grow
use
antimicrobi
hygien
aid
increas
use
plastic
new
applic
futur
develop
antibacteri
materi
focu
creat
surfac
would
trigger
host
defenc
system
possess
excel
biocompat
resist
bacteri
adher
releas
antibacteri
activ
substanc
control
way
addit
antibacteri
materi
easi
make
possess
high
antibacteri
activ
togeth
broad
spectrum
antibacteri
properti
fast
recoveri
capabl
sustain
deliveri
antimicrobi
agent
design
antibacteri
materi
mainli
focus
surfac
treatment
mani
advantag
surfac
treatment
incorpor
antiinfect
agent
onto
surfac
medic
devic
advantag
includ
larg
varieti
antiinfect
agent
surfac
select
straightforward
inexpens
modif
exist
devic
possibl
without
chang
devic
bulk
properti
exampl
biosaf
antimicrobi
activ
ingredi
quaternari
ammonium
compound
made
usabl
plastic
organofunct
silan
technolog
biosaf
perman
nonmigr
nontox
lower
cost
silverbas
addit
could
exampl
futur
antibacteri
devic
continu
effort
futur
requir
advanc
understand
pathophysiolog
devicerel
infect
effect
function
human
homeostasi
microstructur
chemic
structur
adher
mechan
receptor
site
compromis
tissu
factor
might
effect
block
initi
bacteri
adher
progress
fundament
understand
encourag
appear
new
technolog
provid
superior
antiinfect
devic
addit
new
technolog
includ
nanomedicin
antibacteri
effect
tissu
engin
bodi
repair
gener
great
interest
clinic
research
